An Early Phase 2 Clinical Study of KSP-0243

Summary

A phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study to administer KSP-0243 or a placebo once daily after breakfast for 8 weeks in 100 patients with mild to moderate active ulcerative colitis.

Timeline

Start

2023-04-27

Primary completion

2024-10-18

Completion

2024-10-18

Drugs

Indications